Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
5.52 USD -1.08% Intraday chart for biote Corp. -0.36% +11.74%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
B. Riley Ups Price Target on Biote to $10 From $9, Maintains Buy Rating MT
CORRECTION : --B. Riley Lowers Bitcoin Depot's Price Target to $4 From $6, Maintains Buy Rating MT
B. Riley Lowers biote's PT to $4 From $6 After Lower-Than-Expected Q4 2023 Results, Says California Regulations Hit Sales Outlook; Maintains Buy Rating MT
Biote Corp. completed the acquisition of Asteria Health. CI
Roth MKM Adjusts Price Target on Biote to $9 From $8, Maintains Buy Rating MT
Transcript : Biote Corp., Q4 2023 Earnings Call, Mar 12, 2024
Biote Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Biote Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (BTMD) BIOTE Reports Q4 Revenue $45.7M, vs. Street Est of $45.7M MT
Biote Corp. Provides Revenue Guidance for 2024 CI
B. Riley Securities Starts biote With Buy Rating, $9 Price Target MT
Jefferies Starts Biote With Buy Rating, $6.55 Price Target MT
Tech Stocks Drag Down Exchange-Traded Funds, Equity Futures Pre-Bell Friday MT
Biote Board Approves $20 Million Share Repurchase Program MT
Biote Corp. announces an Equity Buyback for $20 million worth of its shares. CI
Biote Corp. authorizes a Buyback Plan. CI
Sector Update: Health Care Stocks Mixed Premarket Thursday MT
Roth MKM Trims Price Target on Biote to $7 From $8, Maintains Buy Rating MT
Sector Update: Health Care MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday as Focus Returns to Earnings MT
Biote Shares Sink Premarket Following Acquisition Plan of Asteria, Preliminary Q4 Revenue, 2024 Revenue Outlook MT
Biote Agrees to Acquire Asteria Health for $8.5 Million; Issues Preliminary Q4 Revenue MT
Biote Corp. Provides Revenue Guidance for the Year 2023 CI
Biote Corp. Provides Revenue Guidance for the Fourth Quarter of 2023, First Half and Full Year of 2024 CI
Biote Corp. entered into a definitive agreement to acquire Asteria Health for $9 million. CI
Chart biote Corp.
More charts
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.52 USD
Average target price
8.648 USD
Spread / Average Target
+56.67%
Consensus
  1. Stock Market
  2. Equities
  3. BTMD Stock
  4. News biote Corp.
  5. Earnings Flash (BTMD) BIOTE Reports Q4 Revenue $45.7M, vs. Street Est of $45.7M